Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-βHSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Inclusion Criteria:

• Provision of signed written and dated informed consent
• Have a body mass index (BMI) between 27 and 35 kg/m2
• Waist circumference of >102 cm

Exclusion Criteria:

• History of any clinical significant disease
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
• Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator